Latest news with #OpusGenetics
Yahoo
18-05-2025
- Business
- Yahoo
Opus Genetics, Inc. (NASDAQ:IRD) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
It's been a good week for Opus Genetics, Inc. (NASDAQ:IRD) shareholders, because the company has just released its latest quarterly results, and the shares gained 7.7% to US$1.02. Revenues of US$4.4m crushed expectations, although expenses increased commensurately, with statutory losses hitting US$0.24 per share, -17% above what the analysts expected. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year. We've discovered 4 warning signs about Opus Genetics. View them for free. Taking into account the latest results, the current consensus from Opus Genetics' three analysts is for revenues of US$15.4m in 2025. This would reflect a decent 13% increase on its revenue over the past 12 months. The loss per share is expected to greatly reduce in the near future, narrowing 39% to US$0.78. Before this latest report, the consensus had been expecting revenues of US$13.3m and US$0.81 per share in losses. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a sizeable increase to their revenue forecasts while also reducing the estimated loss as the business grows towards breakeven. Check out our latest analysis for Opus Genetics Yet despite these upgrades, the analysts cut their price target 31% to US$7.33, implicitly signalling that the ongoing losses are likely to weigh negatively on Opus Genetics' valuation. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. Currently, the most bullish analyst values Opus Genetics at US$8.00 per share, while the most bearish prices it at US$6.00. With such a narrow range of valuations, the analysts apparently share similar views on what they think the business is worth. Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. We would highlight that Opus Genetics' revenue growth is expected to slow, with the forecast 17% annualised growth rate until the end of 2025 being well below the historical 44% p.a. growth over the last five years. Juxtapose this against the other companies in the industry with analyst coverage, which are forecast to grow their revenues (in aggregate) 17% annually. Factoring in the forecast slowdown in growth, it looks like Opus Genetics is forecast to grow at about the same rate as the wider industry. The most obvious conclusion is that the analysts made no changes to their forecasts for a loss next year. They also upgraded their revenue forecasts, although the latest estimates suggest that Opus Genetics will grow in line with the overall industry. Furthermore, the analysts also cut their price targets, suggesting that the latest news has led to greater pessimism about the intrinsic value of the business. With that in mind, we wouldn't be too quick to come to a conclusion on Opus Genetics. Long-term earnings power is much more important than next year's profits. We have estimates - from multiple Opus Genetics analysts - going out to 2027, and you can see them free on our platform here. It is also worth noting that we have found 4 warning signs for Opus Genetics (1 is potentially serious!) that you need to take into consideration. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
18-05-2025
- Business
- Yahoo
Opus Genetics, Inc. (NASDAQ:IRD) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
It's been a good week for Opus Genetics, Inc. (NASDAQ:IRD) shareholders, because the company has just released its latest quarterly results, and the shares gained 7.7% to US$1.02. Revenues of US$4.4m crushed expectations, although expenses increased commensurately, with statutory losses hitting US$0.24 per share, -17% above what the analysts expected. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year. We've discovered 4 warning signs about Opus Genetics. View them for free. Taking into account the latest results, the current consensus from Opus Genetics' three analysts is for revenues of US$15.4m in 2025. This would reflect a decent 13% increase on its revenue over the past 12 months. The loss per share is expected to greatly reduce in the near future, narrowing 39% to US$0.78. Before this latest report, the consensus had been expecting revenues of US$13.3m and US$0.81 per share in losses. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a sizeable increase to their revenue forecasts while also reducing the estimated loss as the business grows towards breakeven. Check out our latest analysis for Opus Genetics Yet despite these upgrades, the analysts cut their price target 31% to US$7.33, implicitly signalling that the ongoing losses are likely to weigh negatively on Opus Genetics' valuation. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. Currently, the most bullish analyst values Opus Genetics at US$8.00 per share, while the most bearish prices it at US$6.00. With such a narrow range of valuations, the analysts apparently share similar views on what they think the business is worth. Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. We would highlight that Opus Genetics' revenue growth is expected to slow, with the forecast 17% annualised growth rate until the end of 2025 being well below the historical 44% p.a. growth over the last five years. Juxtapose this against the other companies in the industry with analyst coverage, which are forecast to grow their revenues (in aggregate) 17% annually. Factoring in the forecast slowdown in growth, it looks like Opus Genetics is forecast to grow at about the same rate as the wider industry. The most obvious conclusion is that the analysts made no changes to their forecasts for a loss next year. They also upgraded their revenue forecasts, although the latest estimates suggest that Opus Genetics will grow in line with the overall industry. Furthermore, the analysts also cut their price targets, suggesting that the latest news has led to greater pessimism about the intrinsic value of the business. With that in mind, we wouldn't be too quick to come to a conclusion on Opus Genetics. Long-term earnings power is much more important than next year's profits. We have estimates - from multiple Opus Genetics analysts - going out to 2027, and you can see them free on our platform here. It is also worth noting that we have found 4 warning signs for Opus Genetics (1 is potentially serious!) that you need to take into consideration. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17-05-2025
- Business
- Yahoo
Opus Genetics First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
Revenue: US$4.37m (up 155% from 1Q 2024). Net loss: US$8.19m (loss widened by 15% from 1Q 2024). US$0.24 loss per share. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue exceeded analyst estimates by 34%. Earnings per share (EPS) missed analyst estimates by 17%. Looking ahead, revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US. Performance of the American Biotechs industry. The company's shares are up 7.7% from a week ago. What about risks? Every company has them, and we've spotted 4 warning signs for Opus Genetics (of which 1 can't be ignored!) you should know about. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
15-05-2025
- Business
- Yahoo
Opus Genetics, Inc. (IRD) Reports Q1 Loss, Tops Revenue Estimates
Opus Genetics, Inc. (IRD) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.29 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 5.88%. A quarter ago, it was expected that this company would post a loss of $0.34 per share when it actually produced a loss of $1.27, delivering a surprise of -273.53%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Opus Genetics, Inc. , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $4.37 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 56.07%. This compares to year-ago revenues of $1.71 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Opus Genetics, Inc. Shares have lost about 20.2% since the beginning of the year versus the S&P 500's gain of 0.2%. While Opus Genetics, Inc. Has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Opus Genetics, Inc. Mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.26 on $2.94 million in revenues for the coming quarter and -$1.09 on $12.53 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 28% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, VistaGen Therapeutics, Inc. (VTGN), has yet to report results for the quarter ended March 2025. This company is expected to post quarterly loss of $0.53 per share in its upcoming report, which represents a year-over-year change of -112%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. VistaGen Therapeutics, Inc.'s revenues are expected to be $0.36 million, up 82% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Opus Genetics, Inc. (IRD) : Free Stock Analysis Report VistaGen Therapeutics, Inc. (VTGN) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15-04-2025
- Business
- Yahoo
PRISM MarketView Spotlights Opus Genetics in New Q&A with CEO George Magrath
Feature Details Company Milestones and 2025 Catalysts Across Gene Therapy and Ophthalmic Programs NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- PRISM MarketView today published a Q&A feature with Dr. George Magrath, Chief Executive Officer of Opus Genetics, Inc. ('Opus Genetics' or the 'Company') (Nasdaq: IRD), a clinical-stage gene therapy company developing treatments for inherited retinal diseases (IRDs) and broader ophthalmic George Magrath, Chief Executive Officer of Opus Genetics, Inc. In the interview, Dr. Magrath outlines Opus Genetics' recent milestones, including: Completion of enrollment in two Phase 3 clinical trials: VEGA-3 for presbyopia and LYNX-2 for post-LASIK night vision disturbances; FDA Fast Track designation for phentolamine ophthalmic solution to treat chronic night driving impairment; and Upcoming data presentations for OPGx-LCA5, an AAV-based gene therapy targeting Leber congenital amaurosis 5. The feature also explores Opus Genetics' strategy to seek to build a repeatable gene therapy platform and anticipated clinical milestones throughout 2025.'With multiple regulatory milestones and clinical readouts, as well as an expanding pipeline, 2025 has the potential to be a pivotal year for Opus Genetics,' said Dr. Magrath. The full Q&A, published by PRISM MarketView, is available here: Opus GeneticsOpus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with IRDs and other treatments for ophthalmic disorders. Our pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Our most advanced investigational gene therapy program is designed to address mutations in the LCA5 gene, which encodes the lebercilin protein and is currently being evaluated in a Phase 1/2 open-label, dose-escalation trial, with encouraging early data. Our pipeline also includes BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy. Phentolamine Ophthalmic Solution 0.75% is currently being evaluated in Phase 3 trials for presbyopia and dim (mesopic) light vision disturbances. We have reached agreement with the FDA under SPA for a Phase 3 trial to evaluate oral APX3330 for the treatment of DR more information, please visit Forward-Looking Statements This article contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements concerning data from and future enrollment for the Company's clinical trials, the results of the Company's ongoing Phase 1/2 trial with respect to OPGx LCA5, and the Company's pipeline of additional indications. These forward-looking statements relate to the Company, its business prospects and its results of operations and are subject to certain risks and uncertainties posed by many factors and events that could cause its actual business, prospects and results of operations to differ materially from those anticipated by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those described under Part II, Item 1A, 'Risk Factors', in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in the Company's other filings with the U.S. Securities and Exchange Commission (the 'SEC'). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this article. In some cases, you can identify forward-looking statements by the following words: 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'aim,' 'may,' 'ongoing,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'will,' 'would' or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The Company undertakes no obligation to revise any forward-looking statements in order to reflect events or circumstances that might subsequently arise, except as may be required by applicable law. These forward-looking statements are based upon the Company's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation: Failure to successfully integrate our businesses with former Opus Genetics Inc. could have a material adverse effect on our business, financial condition and results of operations; The acquisition of former Opus Genetics Inc. significantly expanded our product pipeline and business operations and shifted our business strategies, which may not improve the value of our common stock; Our gene therapy product candidates are based on a novel technology that is difficult to develop and manufacture, which may result in delays and difficulties in obtaining regulatory approval; Our planned clinical trials may face substantial delays, result in failure, or provide inconclusive or adverse results that may not satisfy FDA requirements to further develop our therapeutic products; Changes in regulatory requirements could result in increased costs or delays in development timelines; We depend heavily on the success of our product pipeline; if we fail to find strategic partners or fail to adequately develop or commercialize our pipeline products, our business will be materially harmed; Others may discover, develop, or commercialize products similar to those in our pipeline before or more successfully than we do or develop generic variants of our products even while our product patents remain active, thereby reducing our market share and potential revenue from product sales; We do not currently have any sales or marketing infrastructure in place and we have limited drug research and discovery capabilities; The future commercial success of our products could significantly depend upon several uncertain factors, including third-party reimbursement practices and the existence of competitors with similar products; Product liability lawsuits against us or our suppliers or manufacturers could cause us to incur substantial liabilities and could limit commercialization of any product candidate that we may develop; Failure to comply with health and safety laws and regulations could lead to material fines ; We have not generated significant revenue from sales of any products and expect to incur losses for the foreseeable future; Our future viability is difficult to assess due to our short operating history and our future need for substantial additional capital, which could be limited by any adverse developments that affect the financial services industry; Raising additional capital may cause our stockholders to be diluted, among other adverse effects; We operate in a highly regulated industry and face many challenges complying to sudden changes in legislative reform or the regulatory environment, which affects our pipeline stability and could impair our ability to compete in international markets; We may not receive regulatory approval to market our developed product candidates within or outside of the U.S.; With respect to any of our product candidates that receive marketing approval, we may be subject to substantial penalties if we fail to comply with applicable regulatory requirements; Our potential relationships with healthcare providers and third-party payors will be subject to certain healthcare laws and regulations, which could expose us to extensive potential liabilities; We rely on third parties for material aspects of our business, such as conducting our nonclinical and clinical trials and supplying and manufacturing bulk drug substances, which exposes us to certain risks; We may be unsuccessful in entering into or maintaining licensing arrangements (such as the Viatris License Agreement) or establishing strategic alliances on favorable terms, which could harm our business; Our current focus on the cash-pay utilization for future sales of RYZUMVI may limit our ability to increase sales or achieve profitability with this product; Inadequate patent protection for our product candidates may result in our competitors developing similar or identical products or technology, which would adversely affect our ability to successfully commercialize; We may be unable to obtain full protection for our intellectual property rights under U.S. or foreign laws; We may become involved in lawsuits for a variety of reasons associated with our intellectual property rights, including alleged infringement suits initiated by third parties; We are dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy; As we grow, we may not be able to operate internationally or adequately develop and expand our sales, marketing, distribution, and other corporate functions, which could disrupt our operations; The market price of our common stock is expected to be volatile and subject to certain dilutive risks associated with our Equity Line of Credit arrangement; and Factors out of our control related to our securities, such as securities litigation or actions of activist stockholders, could adversely affect our business and stock price and cause us to incur significant expenses. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive. Readers are urged to carefully review and consider the various disclosures made by the Company in this statement and in the Company's other reports filed with the SEC that advise interested parties of the risks and factors that may affect the Company's business. All forward-looking statements contained in this article speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by applicable law. About PRISM MarketViewPRISM MarketView is a financial media platform focused on highlighting emerging growth companies and breakthrough innovation across public markets. Through original editorial, video features, and executive Q&A content, PRISM delivers timely insights and elevates visibility for high-potential companies. PRISM also maintains a suite of proprietary indexes tracking momentum across sectors including biotech, AI, and consumer tech. Learn more at PRISM MarketView does not provide investment advice. DisclaimerThis communication was produced by PRISM MarketView, an affiliate of PCG Advisory Inc., (together "PCG"). PCG is not a registered or licensed broker-dealer nor investment adviser. No information contained in this communication constitutes an offer to sell, a solicitation of an offer to buy, or a recommendation of any security. PCG may be compensated by respective clients for publicizing information relating to its clients' securities. See Contact:PRISM MarketViewinfo@ Photos accompanying this announcement are available at:
